ODD announced that it is working with the FDA to reduce regulatory uncertainty for its drug development process.
1 report, 1 independent
Updated Aug 6
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
ODD announced that it is working with the FDA to reduce regulatory uncertainty for its drug development process.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Boston Children's Hospital and Harvard Medical School provided preclinical data for a therapy related to ODD.Sub-event
- The FDA is utilizing generative AI tools like Elsa and Peer AI to aid in drafting clinical and regulatory documents for drug development.Sub-event
ODD is working with the FDA to reduce regulatory uncertainty for drug development.1 source
Keep exploring
The entities involved
Related events
- FDA rule changes are causing delays in product approval, leading to the process exceeding Congressional mandated timeframes.
- FDA approval is the goal for product candidates from Daré Bioscience, Inc.
- The FDA is accused of failing to enforce safety regulations and operating under current rules without in-person oversight.
- FDA is willing to review updated submissions, while biotech hubs leverage AI to ease clinical development bottlenecks.
- FDA guidance changes affect biosimilar approval, impacting Coherus Oncology, Inc.